Janux Therapeutics (JANX) Retained Earnings (2020 - 2026)

Janux Therapeutics (JANX) has reported Retained Earnings for 6 consecutive years, with -$375.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 43.8% year-over-year to -$375.7 million; the TTM figure through Mar 2026 stood at -$375.7 million (down 43.8% YoY), while the FY2025 annual figure was -$351.4 million, down 16345.12% from the prior year.
• Retained Earnings fell to -$375.7 million in Q1 2026 per JANX's latest filing, from -$351.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at $3.7 million in Q2 2025 and bottomed at -$375.7 million in Q1 2026.
• Historically, Retained Earnings has averaged -$147.5 million across 5 years, with a median of -$127.9 million in 2023.
• On a YoY basis, Retained Earnings climbed as much as 101.98% in 2025 and fell as far as 49759.73% in 2025.
• Janux Therapeutics' Retained Earnings stood at -$110.5 million in 2022, then plunged by 52.77% to -$168.8 million in 2023, then surged by 101.28% to $2.2 million in 2024, then plunged by 16345.12% to -$351.4 million in 2025, then slipped by 6.92% to -$375.7 million in 2026.
• Business Quant data shows JANX's Retained Earnings at -$375.7 million in Q1 2026, -$351.4 million in Q4 2025, and -$319.4 million in Q3 2025.